EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

An Early Value Assessment of Biomarker-Guided Precision Medicine for Treatment-Resistant Hypertension: A Headroom and Threshold Analysis

Teebah Abu-Zahra, Sabine Grimm, Mirre Scholte, Ana I Casas, Peter Saliba-Gustafsson, Paolo Parini, Manuela Joore

Applied Health Economics and Health Policy · 2026-11 · 24 (6) · 1093-1108

DOI: 10.1007/s40258-026-01075-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Health Economics and Health Policy, online erschienen am 30.09.2026. Verfasst von Teebah Abu-Zahra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology & Medical Technology Assessment (KEMTA), Maastricht University Medical Centre (MUMC+), Maastricht, The Netherland…. Hauptthemen laut MEDLINE: Hypertension, Precision Medicine, Antihypertensive Agents. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Health and Digital Executive Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionPrecision MedicineAntihypertensive AgentsHumansBiomarkersCost-Benefit AnalysisQuality-Adjusted Life YearsModels, EconomicNetherlandsDecision TreesNADPH Oxidase 5Cost-Effectiveness AnalysisFemaleMaleMiddle Aged

Substanzen

BiomarkersAntihypertensive AgentsNADPH Oxidase 5

Autor:innen und Institutionen

  • Department of Clinical Epidemiology & Medical Technology Assessment (KEMTA), Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands. Teebah.abu-zahra@mumc.nl.
  • Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. Teebah.abu-zahra@mumc.nl.
  • Department of Clinical Epidemiology & Medical Technology Assessment (KEMTA), Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands.
  • Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
  • Departments of Medical Imaging and IQ health, Radboudumc, Nijmegen, The Netherlands.
  • Department of Neurology and Center for Translational Neuro- and Behavioural Sciences (C-TNBS), Clinic for Neurology, University Hospital Essen, Essen, Germany.

Förderung

  • European Health and Digital Executive Agency

Zitieren

APA

Abu-Zahra, T., Grimm, S., Scholte, M., Casas, A. I., Saliba-Gustafsson, P., Parini, P., & Joore, M. (2026). An Early Value Assessment of Biomarker-Guided Precision Medicine for Treatment-Resistant Hypertension: A Headroom and Threshold Analysis. Applied Health Economics and Health Policy, 24(6), 1093-1108. https://doi.org/10.1007/s40258-026-01075-x

Vancouver

Abu-Zahra T, Grimm S, Scholte M, Casas AI, Saliba-Gustafsson P, Parini P, et al. An Early Value Assessment of Biomarker-Guided Precision Medicine for Treatment-Resistant Hypertension: A Headroom and Threshold Analysis. Applied Health Economics and Health Policy. 2026;24(6):1093-1108. doi:10.1007/s40258-026-01075-x

BibTeX
@article{AbuZahra2026,
  author = {Abu-Zahra, Teebah and Grimm, Sabine and Scholte, Mirre and Casas, Ana I and Saliba-Gustafsson, Peter and Parini, Paolo and Joore, Manuela},
  title = {An Early Value Assessment of Biomarker-Guided Precision Medicine for Treatment-Resistant Hypertension: A Headroom and Threshold Analysis},
  journal = {Applied Health Economics and Health Policy},
  year = {2026},
  volume = {24},
  number = {6},
  pages = {1093--1108},
  doi = {10.1007/s40258-026-01075-x}
}
Kostenlos starten →